Talawar’s $285m Nasdaq Debut Fuels Phase IIb Trial of TALA-125 by H2 2028
SNY•Talawar Therapeutics has secured $225m in PIPE funding and holds $60m in trust for a $285m Nasdaq debut, aiming to advance its IL-13/IL-18 bispecific antibody TALA-125 into a Phase IIb proof-of-concept trial with data due in H2 2028. The move positions Talawar to challenge Sanofi’s and Regeneron’s Dupixent in the atopic dermatitis market.
1. Business Combination and Funding
Talawar Therapeutics emerged from a definitive business combination with JATT II Acquisition, securing $225m through a private investment in public equity and retaining $60m in trust, totaling $285m for its Nasdaq debut under ticker TLWR. Lead investors include Access Biotechnology, Bain Capital Life Sciences and RA Capital Management, providing capital to advance its immunology pipeline.
2. TALA-125 Phase IIb Program
The company’s lead candidate, TALA-125, is an IL-13/IL-18 bispecific antibody designed to overcome monotherapy efficacy limits by targeting two complementary pathways in atopic dermatitis. Talawar plans to initiate its Phase IIb proof-of-concept trial and expects a clinical readout in the second half of 2028.
3. Market Opportunity and Competitive Landscape
The atopic dermatitis market across the US, major European countries and Japan is projected to reach $22.4bn by 2033, driven by demand for targeted therapies. Talawar’s bispecific approach aims to capture share from established treatments like Dupixent, currently dominating with broad IL-4/IL-13 inhibition.
4. Additional Pipeline and Future Milestones
Beyond TALA-125, Talawar is developing discovery-phase programmes TALA-307 and TALA-711 in immunology. If the transaction closes in H2 2026, Talawar will be the first spin-out of Khanda Therapeutics, with its Nasdaq listing marking a key milestone ahead of planned clinic entry for TALA-125 in Q1 2027.
